How should we advise patients about the contraceptive patch, given the FDA warning?
Thacker
Holly L
HL
Women's Health Center at The Gault Women's Health and Breast Pavilion, Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA. thackeh@ccf.org
Falcone
Tommaso
T
Atreja
Ashish
A
Jain
Anil
A
Harris
C Martin
CM
D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003376:Counseling; D004338:Drug Combinations; D004363:Drug Utilization; D005003:Ethisterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000009:adverse effects / Q000031:analogs & derivatives*; D010091:Oximes / Q000009:adverse effects; D010817:Physician-Patient Relations; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration; D020246:Venous Thrombosis / Q000139:chemically induced
D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D010091:Oximes; D009644:Norgestrel; D005003:Ethisterone; C449219:norelgestromin